<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00729313</url>
  </required_header>
  <id_info>
    <org_study_id>E-54-52030-053</org_study_id>
    <nct_id>NCT00729313</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae</brief_title>
  <official_title>A Phase III Multicentre Randomised Double-blind Comparative Study of Efficacy and Safety of Lanreotide 30 mg Versus Placebo for Treatment of Patients With Digestive Fistulae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the protocol, is to determine whether lanreotide 30 mg is effective in the
      treatment of patients with digestive fistulae.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether lanreotide 30mg compared to placebo is
      effective on the evolution of drainage volume of digestive fistulae in the 72 hours following
      the beginning of treatment and on the spontaneous closure time of digestive fistulae.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with a reduction of fistula drainage volume &gt; 50% of baseline at 72 hours.</measure>
    <time_frame>Fistula drainage volume on 3rd day.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Closure time of digestive fistulae will be defined by the interval between D0 (day of the first injection) and the date of spontaneous closure of the fistula.</measure>
    <time_frame>Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreatic or duodenal and small intestine fistula closing rate within D60</measure>
    <time_frame>Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of injections received by each patient</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of fistula recurrence during the follow-up period</measure>
    <time_frame>Duration of follow-up period for each patient is of 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of mortality in each group</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Digestive Fistulae</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Lanreotide 30 mg microparticle formulation
One intra-muscular injection.
A (maximum) 60 day &quot;treatment&quot; period (6 intra-muscular injections of lanreotide 30 mg microparticle formulation every 10 days): according to the patient's treatment response at 72h
For non-responders patients lanreotide will be stopped.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One intra-muscular injection.
A (maximum) 60 day &quot;treatment&quot; period (6 intra-muscular injections of placebo every 10 days): according to the patient's treatment response at 72h.
Non-responder patients having received placebo on the first injection should receive an open-labelled lanreotide treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanreotide microparticles</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with pancreatic, duodenal, or small intestine fistula

          -  Patient with simple, externalised fistula

          -  Patient with fistula for which a medical conservative treatment is considered

          -  Patient with:

          -  for pancreatic fistulae: a mean drainage volume more than or equal to 100 ml/24h over
             48 hours or more than or equal to 50 ml / 24h over 3 days and a concentration of
             amylase in the drainage fluid 3 times higher than in the serum over at least 2 or 3
             consecutive days respectively,

          -  for duodenal and small intestine fistulae: a mean drainage volume more than or equal
             to 100ml/24h over 2 days

        Exclusion Criteria:

          -  Patient expected to require a surgical treatment of the fistula during the study

          -  Patient having uncontrolled intra-abdominal sepsis; Crohn's disease; radiotherapy
             lesions of the small bowel; a mesenteric vascular insufficiency; a fistula localised
             in cancer-infiltrated areas; a distal obstruction; an exposed fistula of the small
             intestine; or intra-abdominal foreign bodies.

          -  Patient receiving long-term corticotherapy

          -  Patient having received any somatostatin analogue as curative treatment of the fistula
             or any PRF somatostatin analogue within the previous month.

          -  Patient having previously undergone a transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joëlle Blumberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU J. Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital A. Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bicêtre</name>
      <address>
        <city>Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu</name>
      <address>
        <city>Lyon</city>
        <zip>69288</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Surgery n.a. A.V. Vishnevsky</name>
      <address>
        <city>Moscow</city>
        <zip>113811</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Centre of Surgery</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Russian Federation</country>
  </location_countries>
  <results_reference>
    <citation>Gayral F, Campion JP, Regimbeau JM, Blumberg J, Maisonobe P, Topart P, Wind P; Lanreotide Digestive Fistula. Randomized, placebo-controlled, double-blind study of the efficacy of lanreotide 30 mg PR in the treatment of pancreatic and enterocutaneous fistulae. Ann Surg. 2009 Dec;250(6):872-7.</citation>
    <PMID>19953707</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2008</study_first_submitted>
  <study_first_submitted_qc>August 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2008</study_first_posted>
  <last_update_submitted>June 18, 2012</last_update_submitted>
  <last_update_submitted_qc>June 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2012</last_update_posted>
  <responsible_party>
    <name_title>Joelle Blumberg</name_title>
    <organization>Ipsen</organization>
  </responsible_party>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

